From laser vision correction to adjustable lens implants, the Center for Refractive Solutions at New York Eye and Ear ...

To conduct the study, the investigators obtained data on coffee consumption from genome‐wide association studies (GWAS) and ...

Ocugen has announced the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) amendment to ...

Funding will support continued product development, while the board is composed of “global leaders in posterior and anterior ...

A look at current therapies, clinical trial results, patient education, and emerging options for managing this progressive ...

Assistive devices empower patients with central vision loss to regain independence, enhancing daily activities and reducing ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

The center aims to optimize patients' vision with a range of cataract and corneal refractive procedures and minimize reliance ...

Fluorescence lifetime imaging ophthalmoscopy is emerging as a valuable tool to reveal previously hidden links between retinal ...

Aldeyra had received 2 complete response letters (CRL) from the FDA in April 2025 and November 2023 for past submissions.

Eyecyte-RPE phase 1 study showed promising safety and efficacy, with no serious adverse events and significant vision ...

In a study of 10 patients, the LYNX LIO achieved a mean treatment time of 16 minutes, 43 seconds, with 3,489 spots delivered ...